Paper40539780
Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.
Xu J-Z and 13 others. J Virol, 2025. Cited by 8 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis. Papers, record 40539780. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40539780
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Oncolytic Virotherapy | Major topic |
| Oncolytic Viruses | Major topic |
| Humans | |
| Treatment Outcome |
Source PubMed
References113
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,298,410 | Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27298410 | PubMed |
| 2 | 35,116,288 | The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. | Transl Cancer Res | 2021 | https://conductscience.org/library/papers/35116288 | PubMed |
| 3 | 39,820,126 | Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial). | Nat Cancer | 2025 | https://conductscience.org/library/papers/39820126 | PubMed |
| 4 | 36,651,961 | Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/36651961 | PubMed |
| 5 | 32,052,079 | Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients. | Cancer Immunol Immunother | 2020 | https://conductscience.org/library/papers/32052079 | PubMed |
| 6 | 34,464,163 | Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34464163 | PubMed |
| 7 | 39,826,543 | Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. | Cell | 2025 | https://conductscience.org/library/papers/39826543 | PubMed |
| 8 | 39,414,325 | First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/39414325 | PubMed |
| 9 | 37,292,376 | A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. | Front Pediatr | 2023 | https://conductscience.org/library/papers/37292376 | PubMed |
| 10 | 33,875,611 | Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/33875611 | PubMed |
| 11 | 36,631,681 | Therapy with oncolytic viruses: progress and challenges. | Nat Rev Clin Oncol | 2023 | https://conductscience.org/library/papers/36631681 | PubMed |
| 12 | 28,529,585 | Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28529585 | PubMed |
| 13 | 19,287,305 | Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. | Anticancer Drugs | 2009 | https://conductscience.org/library/papers/19287305 | PubMed |
| 14 | 33,219,014 | A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33219014 | PubMed |
| 15 | 36,402,738 | The emerging field of oncolytic virus-based cancer immunotherapy. | Trends Cancer | 2023 | https://conductscience.org/library/papers/36402738 | PubMed |
| 16 | 39,915,002 | Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/39915002 | PubMed |
| 17 | 37,060,176 | Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial. | Mol Ther | 2023 | https://conductscience.org/library/papers/37060176 | PubMed |
| 18 | 10,932,224 | a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. | Nat Med | 2000 | https://conductscience.org/library/papers/10932224 | PubMed |
| 19 | 31,563,865 | How to perform a meta-analysis with R: a practical tutorial. | Evid Based Ment Health | 2019 | https://conductscience.org/library/papers/31563865 | PubMed |
| 20 | 29,653,857 | A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. | Clin Colorectal Cancer | 2018 | https://conductscience.org/library/papers/29653857 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,897,128 | Matrix metalloproteinase-guided targeting of vesicular stomatitis virus to tumors following systemic administration. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42897128 | PubMed |
| 42,317,522 | Advances in oncolytic virus delivery strategies and challenges in clinical translation. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42317522 | PubMed |
| 41,618,502 | Mathematical Modeling of the Role of Cytokines in Sindbis Virus Treatment of Glioblastoma. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/41618502 | PubMed |
| 41,294,689 | Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends. | Curr Oncol | 2025 | https://conductscience.org/library/papers/41294689 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40539780
GET https://conductscience.org/api/papers/v1/40539780/references?page=2